A Phase I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas
Latest Information Update: 15 Oct 2024
At a glance
- Drugs Abemaciclib (Primary)
- Indications Neurofibroma; Neurofibromatosis 1; Plexiform neurofibroma
- Focus Adverse reactions
- 17 Apr 2024 Planned number of patients changed from 50 to 55.
- 13 Oct 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 13 Oct 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.